Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05192798 2025-02-27

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Phase 2 Recruiting

128 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2 Recruiting

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase 3 Terminated

80 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Phase 2 Unknown

58 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

140 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Phase 1 Completed

98 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03243838 2022-02-02

LANCET

Phase 2 Completed

31 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03932526 2019-04-30

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Phase 2 Unknown

184 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03775928 2018-12-14

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Phase 2 Unknown

80 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03348098 2017-11-28

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Phase 2 Unknown

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01176669 2015-09-09

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Phase 2 Completed

60 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

FASCINATE-N

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

FUTURE

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

LANCET

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients